Alnylam Pharmaceuticals (ALNY) Retained Earnings (2009 - 2026)
Alnylam Pharmaceuticals (ALNY) posted Retained Earnings of -$24.9 million for Q1 2026, up 99.63% on a QoQ basis from -$6.7 billion in Q4 2025, and up 99.66% year-over-year from -$12.5 million in Q1 2025.
Alnylam Pharmaceuticals (ALNY) Retained Earnings (2009 - 2026) Analysis & Trends
Alnylam Pharmaceuticals' Retained Earnings history runs 18 years deep, the most recent figure standing at -$24.9 million for Q1 2026.
- Quarterly Retained Earnings rose 99.66% year-over-year to -$24.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$24.9 million (up 99.66% YoY) and the FY2025 annual result came in at -$6.7 billion, up 8.03% from the prior year.
- Retained Earnings was -$24.9 million for Q1 2026 at Alnylam Pharmaceuticals, up from -$6.7 billion in the prior quarter.
- Across five years, Retained Earnings topped out at -$21.8 million in Q3 2025 and bottomed at -$7.3 billion in Q1 2025.
- A 5-year average of -$3.3 billion and a median of -$44.7 million in 2022 frame the typical range for Retained Earnings.
- Peak annual rise in Retained Earnings reached 99.7% in 2025, while the deepest fall reached 27116.64% in 2025.
- Alnylam Pharmaceuticals' Retained Earnings stood at -$44.7 million in 2022, then plunged by 15597.57% to -$7.0 billion in 2023, then slipped by 3.97% to -$7.3 billion in 2024, then grew by 8.03% to -$6.7 billion in 2025, then soared by 99.63% to -$24.9 million in 2026.
- Business Quant data shows ALNY's Retained Earnings at -$24.9 million in Q1 2026, -$6.7 billion in Q4 2025, and -$21.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -527.87 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | -27.89 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -279.01 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 12.91 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 14.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 11.90 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -622,000.00 |
| 10 | Alnylam Pharmaceuticals | 36.08 Bn | 33.07 Bn | 959.66 Mn | -24.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -24.89 Mn |
| Dec 31, 2025 | -6.70 Bn |
| Sep 30, 2025 | -21.78 Mn |
| Jun 30, 2025 | -29.95 Mn |
| Mar 31, 2025 | -7.35 Bn |
| Dec 31, 2024 | -7.29 Bn |
| Sep 30, 2024 | -7.20 Bn |
| Jun 30, 2024 | -34.64 Mn |
| Mar 31, 2024 | -26.99 Mn |
| Dec 31, 2023 | -7.01 Bn |
| Sep 30, 2023 | -32.34 Mn |
| Jun 30, 2023 | -7.02 Bn |
| Mar 31, 2023 | -6.74 Bn |
| Dec 31, 2022 | -44.65 Mn |
| Sep 30, 2022 | -43.78 Mn |
| Jun 30, 2022 | -42.22 Mn |
| Mar 31, 2022 | -5.68 Bn |
| Dec 31, 2021 | -33.26 Mn |
| Sep 30, 2021 | -34.23 Mn |
| Jun 30, 2021 | -4.98 Bn |